CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Elmetwali, Taha ^a   Searle, Peter F ^a   McNeish, Iain ^a   Young, Lawrence S ^a   Palmer, Daniel H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; METALLOPROTEINASE; PROTEINASE INHIBITOR;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA; CARCINOMA CELL; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; IN VIVO STUDY; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; VIRUS REPLICATION; AMINO ACID SEQUENCE; CELL PROLIFERATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRIDAE; AMINO ACID SEQUENCE; APOPTOSIS; CD40 LIGAND; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; HUMANS; METALLOPROTEASES; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PROTEASE INHIBITORS; VIRUS REPLICATION;

EID: 77952313584     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-52     Document Type: Article

References (29)

1. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000, 67(1):2-17.
2. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004, 4(4):360-7. 10.1016/j.coph.2004.02.008, 15251129.
3. Challa A, Eliopoulos AG, Holder MJ, Burguete AS, Pound JD, Chamba A, Grafton G, Armitage RJ, Gregory CD, Martinez-Valdez H, Young L, Gordon J. Population depletion activates autonomous CD154-dependent survival in biopsy like Burkitt lymphoma cells. Blood 2002, 99(9):3411-8. 10.1182/blood.V99.9.3411, 11964311.
4. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Terry N, Reid PS, Ford RJ. A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 2002, 16(1):37-50. 10.1016/S1074-7613(01)00258-8, 11825564.
5. Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, Gordon J, Murray PG, Young LS, Eliopoulos AG. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 2005, 24(53):7913-23. 10.1038/sj.onc.1208929, 16091748.
6. Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P, Gordon J, Selby PJ, Trejdosiewicz LK. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst 2002, 94(18):1381-95.
7. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 2006, 13(10):1789-801. 10.1038/sj.cdd.4401859, 16429118.
8. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004, 279(2):1010-9. 10.1074/jbc.M303820200, 14581487.
9. He TC, Zhou S, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998, 95(5):2509-14. 10.1073/pnas.95.5.2509, 19394, 9482916.
10. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006, 11:1696-701. 10.2741/1915, 16368548.
11. Knox PG, Milner AE, et al. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol 2003, 170(2):677-85.
12. Graf D, Muller S, et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995, 25(6):1749-54. 10.1002/eji.1830250639, 7615003.
13. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, Gauchat JF, Bernard A, Allet B, Bonnefoy JY. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995, 270:7025-7028. 10.1074/jbc.270.13.7025, 7706236.
14. Heise C, Hermiston T, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000, 6(10):1134-9. 10.1038/80474, 11017145.
15. Afford SC, Randhawa S, et al. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med 1999, 189(2):441-6. 10.1084/jem.189.2.441, 2192998, 9892626.
16. Eliopoulos AG, Dawson CW, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996, 13(10):2243-54.
17. Eliopoulos AG, Davies C, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000, 20(15):5503-15. 10.1128/MCB.20.15.5503-5515.2000, 86001, 10891490.
18. Dyson N, Guida P, et al. Adenovirus E1A makes two distinct contacts with the retinoblastoma protein. J Virol 1992, 66(7):4606-11. 241277, 1534854.
19. Fattaey AR, Harlow E, et al. Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes. Mol Cell Biol 1993, 13(12):7267-77. 364797, 8246949.
20. Berkner KL, Sharp PA. Generation of adenovirus by transfection of plasmids. Nucleic Acids Res 1983, 11(17):6003-20. 10.1093/nar/11.17.6003, 326332, 6310523.
21. Kelly TJ, Lewis AM. Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian virus 40 genome. J Virol 1973, 12(3):643-52. 356673, 4355861.
22. Flint SJ, Wewerka-Lutz Y, et al. Adenovirus transcription. II. RNA sequences complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1- and AD2+ND3-infected cells. J Virol 1975, 16(3):662-73. 354714, 169392.
23. Wold WS, Deutscher SL, Takemori N, Bhat BM, Magie SC. Evidence that AGUAUAUGA and CCAAGAUGA initiate translation in the same mRNA region E3 of adenovirus. Virology 1986, 148(1):168-80. 10.1016/0042-6822(86)90412-5, 3753630.
24. Benedict CA, Norris PS, Prigozy TI, Bodmer JL, Mahr JA, Garnett CT, Martinon F, Tschopp J, Gooding LR, Ware CF. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem 2001, 276(5):3270-8. 10.1074/jbc.M008218200, 11050095.
25. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol 1999, 11(4):380-6. 10.1016/S0952-7915(99)80064-8, 10448144.
26. Liu Y, Xia D, et al. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 2005, 12(2):122-32. 10.1038/sj.cgt.7700757, 15565183.
27. Kikuchi T, Miyazawa N, et al. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000, 60(22):6391-5.
28. Tomihara K, Kato K, et al. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Gene Ther 2008, 15(3):203-13. 10.1038/sj.gt.3303056, 17989706.
29. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E, Schmidt-Wolf IG, Caselmann WH, Sauerbruch T, Schmitz V. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 2008, 48(1):157-68. 10.1002/hep.22296, 18537185.